Royal Philips (NYSE: PHG, AEX: PHIA) and HeartFlow, Inc. announced today that they have entered into a collaboration agreement with the goal of improving access to diagnostic and planning tools for interventional cardiologists evaluating and treating patients with suspected coronary artery disease (CAD). Under the agreement, Philips will promote the use of the 
labfolder and the German Accelerator Life Sciences (GALS), an initiative supported by the German Federal Ministry for Economic Affairs and Energy (BMWi), have announced the initiation of an extensive collaboration supporting the company's expansion into the North American markets. With thousands of users and a growing number of customers in the U.S. already, the newly established Cambridge office will accelerate those efforts and support customer relations. 
The Lyfebulb-Novo Nordisk Innovation Summit 2017 will recognize and empower international Patient Entrepreneurs with big ideas that disrupt the future of diabetes management. Patient Entrepreneurs have a unique ability to create value-adding disease management solutions beyond therapy. The aim is to support patient-driven innovation and laser-focus on improving the quality of life for those living with diabetes. 
Parallels are not often drawn between the life-saving efforts of the NHS and the supernatural investigations of the fictional FBI agents Mulder and Scully. But with speakers ranging from renowned characters like Dr Ben Goldacre, through to think tanks and those at the forefront of connecting the UK's health and care services, Joined-up Health & Care 2017 provided insights and truths worthy of exposure. 
Bolton NHS Foundation Trust has selected Allscripts Sunrise EHR as it continues to focus on improving the quality of care delivered to patients. An integrated care organization, Bolton NHS Foundation Trust serves patients from communities at Royal Bolton Hospital and at more than 20 health centers and clinics. An international report published by Royal Philips (NYSE: PHG; AEX: PHIA) reveals that our beleaguered NHS is more integrated than we realise and, in contrast with some other countries, both the public and HCPs are positive about the benefits offered by connected care technologies. Royal Philips (NYSE: PHG; AEX: PHIA), a global leader in health technology, today announced that it has completed the acquisition of The Spectranetics Corporation (NASDAQ: SPNC), a U.S.-based global leader in vascular intervention and lead management solutions. Spectranetics' financial results will be consolidated as part of Philips’ Image-Guided Therapy business group as of August 9, 2017.